Timely recognition of cardiovascular toxicity by anticancer agents: A common objective of the pharmacologist, oncologist and cardiologist

Cardiovascular Toxicology

Volumn 12, Issue 2, 2012, Pages 93-107

  Bonura, Francesca ^a   Di Lisi, Daniela ^a   Novo, Salvatore ^a   D'Alessandro, Natale ^a  

^a UNIVERSITY OF PALERMO   (Italy)

Author keywords

Cardiotoxicity; Echocardiography; New anticancer drugs; Tissue Doppler

Indexed keywords

AMSACRINE; ANTHRACYCLINE DERIVATIVE; ANTHRAQUINONE DERIVATIVE; ARSENIC TRIOXIDE; BEVACIZUMAB; BLEOMYCIN; CAPECITABINE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DASATINIB; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; IMATINIB; LAPATINIB; LENALIDOMIDE; METHOTREXATE; MITOMYCIN C; NILOTINIB; PACLITAXEL; SORAFENIB; SUNITINIB; TAMOXIFEN; TAXANE DERIVATIVE; THALIDOMIDE; TRASTUZUMAB; UNINDEXED DRUG; VINCA ALKALOID; VORINOSTAT;

ANGINA PECTORIS; ANGIOCARDIOGRAPHY; ANTINEOPLASTIC ACTIVITY; ARTERIAL THROMBOEMBOLISM; BREAST CANCER; BREAST METASTASIS; CARDIOTOXICITY; COLORECTAL CANCER; CONTRAST ENHANCEMENT; CUTANEOUS T CELL LYMPHOMA; DIFFUSION WEIGHTED IMAGING; DIZZINESS; DRUG HYPERSENSITIVITY; DRUG POTENTIATION; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG TARGETING; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; HEART ARRHYTHMIA; HEART DEATH; HEART EJECTION FRACTION; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE BIOPSY; HEART MUSCLE ISCHEMIA; HUMAN; HYPERTENSION; HYPOTENSION; HYPOTHYROIDISM; ISCHEMIC HEART DISEASE; KIDNEY CANCER; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; LUNG NON SMALL CELL CANCER; MULTIPLE MYELOMA; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OXIDATIVE STRESS; PERICARDITIS; PHARMACOGENETICS; PHYSICIAN; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; QT PROLONGATION; REVIEW; SIDE EFFECT; SOFT TISSUE SARCOMA; STRESS ECHOCARDIOGRAPHY; THROMBOEMBOLISM; TISSUE DOPPLER IMAGING; VENOUS THROMBOEMBOLISM;

ANIMALS; ANTINEOPLASTIC AGENTS; CARDIOLOGY; CARDIOTOXINS; CARDIOVASCULAR DISEASES; CARDIOVASCULAR SYSTEM; HUMANS; LABORATORY PERSONNEL; MEDICAL ONCOLOGY; PHARMACOLOGY; PHYSICIAN'S ROLE; PROFESSIONAL ROLE; TIME FACTORS;

EID: 84864669663     PISSN: 15307905     EISSN: 15590259     Source Type: Journal    
DOI: 10.1007/s12012-011-9141-z     Document Type: Review

References (115)

1. Chen, M. H., Kerkelä, R., & Force, T. (2008). Mechanisms of cardiac dysfunction associated with tyrosine kinase inhibitor cancer therapeutics. Circulation, 118, 84-95.
2. Hauben, M., Reich, L., & Chung, S. (2004). Postmarketing surveillance of potentially fatal reactions to oncology drugs: Potential utility of two signal-detection algorithms. European Journal of Clinical Pharmacology, 60, 747-750.
3. Edwards, B. J., Gounder, M., McKoy, J. M., Boyd, I., Farrugia, M., Migliorati, C., et al. (2008). Pharmacovigilance and reporting oversight in US FDA fast-track process: Bisphospho-nates and osteonecrosis of the jaw. The Lancet Oncology, 9, 1166-1172.
4. Seidman, A., Hudis, C., Pierri, M. K., Shak, S., Paton, V., Ashby, M., et al. (2002). Cardiac dysfunction in the trastuzumab clinical trials experience. Journal of Clinical Oncology, 20, 1215-1221.
5. Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., et al. (2001). Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. New England Journal of Medicine, 344, 783-792.
6. Zhao, Y. Y., Sawyer, D. R., Baliga, R. R., Opel, D. J., Han, X., Marchionni, M. A., et al. (1998). Neuregulins promote survival and growth of cardiac myocytes. Persistence of ErbB2 and ErbB4 expression in neonatal and adult ventricular myocytes. Journal of Biological Chemistry, 273, 10261-10269.
7. Kuramochi, Y., Guo, X., & Sawyer, D. B. (2006). Neuregulin activates erbB2-dependent src/FAK signaling and cytoskeletal remodeling in isolated adult rat cardiac myocytes. Journal of Molecular and Cellular Cardiology, 41, 228-235.
8. Okoshi, K., Nakayama, M., Yan, X., Okoshi, M. P., Schuldt, A. J., Marchionni, M. A., et al. (2004). Neuregulins regulate cardiac parasympathetic activity: Muscarinic modulation of beta-adrenergic activity in myocytes from mice with neuregulin-1 gene deletion. Circulation, 110, 713-717.
9. Pegram, M., & Ngo, D. (2006). Application and potential limitations of animal models utilized in the development of trast-uzumab (Herceptin): A case study. Advanced Drug Delivery Reviews, 58, 723-734.
10. Crone, S. A., Zhao, Y. Y., Fan, L., Gu, Y., Minamisawa, S., Liu, Y., et al. (2002). ErbB2 is essential in the prevention of dilated cardiomyopathy. Nature Medicine, 8, 459-465.
11. Ewer, M. S., Vooletich, M. T., Durand, J. B., Woods, M. L., Davis, J. R., Valero, V., et al. (2005). Reversibility of trast-uzumab-related cardiotoxicity: New insights based on clinical course and response to medical treatment. Journal of Clinical Oncology, 23, 7820-7826.
12. de Azambuja, E., Bedard, P. L., Suter, T., & Piccart-Gebhart, M. (2009). Cardiac toxicity with anti-HER-2 therapies-what have we learned so far? Targeted Oncology, 4, 77-88.
13. Guglin, M., Hartlage, G., Reynolds, C., Chen, R., & Patel, V. (2009). Trastuzumab-induced cardiomyopathy: Not as benign as it looks? A retrospective study. Journal of Cardiac Failure, 15, 651-657.
14. Beauclair, S., Formento, P., Fischel, J. L., Lescaut, W., Largil-lier, R., Chamorey, E., et al. (2007). Role of the HER2 [Ile655Val] genetic polymorphism in tumorogenesis and in the risk of trastuzumab-related cardiotoxicity. Annals of Oncology, 18, 1335-1341.
15. Spector, N. L., Yarden, Y., Smith, B., Lyass, L., Trusk, P., Pry, K., et al. (2007). Activation of AMP-activated protein kinase by human EGF receptor 2/EGF receptor tyrosine kinase inhibitor protects cardiac cells. Proceedings of the National Academy of Sciences of the United States of America, 104, 10607-10612.
16. Kerkelä, R., Grazette, L., Yacobi, R., Iliescu, C., Patten, R., Beahm, C., et al. (2006). Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nature Medicine, 12, 908-916.
17. Fernández, A., Sanguino, A., Peng, Z., Ozturk, E., Chen, J., Crespo, A., et al. (2007). An anticancer C-kit kinase inhibitor is reengineered to make it more active and less cardiotoxic. Journal of Clinical Investigation, 117, 4044-4054.
18. Wolf, A., Couttet, P., Dong, M., Grenet, O., Heron, M., Junker, U., et al. (2010). Imatinib does not induce cardiotoxicity at clinically relevant concentrations in preclinical studies. Leukemia research, 34, 1180-1188.
19. Turrisi, G., Montagnani, F., Grotti, S., Marinozzi, C., Bolognese, L., & Fiorentini, G. (2010). Congestive heart failure during i-matinib mesylate treatment. International Journal of Cardiology, 145, 148-150.
20. Trent, J. C., Patel, S. S., Zhang, J., Araujo, D. M., Plana, J. C., Lenihan, D. J., et al. (2010). Rare incidence of congestive heart failure in gastrointestinal stromal tumor and other sarcoma patients receiving imatinib mesylate. Cancer, 116, 184-192.
21. Johnson, F. M., Agrawal, S., Burris, H., Rosen, L., Dhillon, N., Hong, D., et al. (2010). Phase 1 pharmacokinetic and drug-interaction study of dasatinib in patients with advanced solid tumors. Cancer, 116, 1582-1591.
22. Chu, T. F., Rupnick, M. A., Kerkela, R., Dallabrida, S. M., Zurakowski, D., Nguyen, L., et al. (2007). Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet, 370, 2011-2019.
23. Schmidinger, M., Zielinski, C. C., Vogl, U. M., Bojic, A., Bojic, M., Schukro, C., et al. (2008). Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma. Journal of Clinical Oncology, 26, 5204-5212.
24. Di Lorenzo, G., Autorino, R., Bruni, G., Cartenì, G., Ricevuto, E., Tudini, M., et al. (2009). Cardiovascular toxicity following sunitinib therapy in metastatic renal cell carcinoma: A multicenter analysis. Annals of Oncology, 20, 1535-1542.
25. Torino, F., Torino, F., Corsello, S. M., Longo, R., Barnabei, A., & Gasparini, G. (2009). Hypothyroidism related to tyrosine kinase inhibitors: An emerging toxic effect of targeted therapy. Nature Reviews Clinical Oncology, 6, 219-229.
26. Hasinoff, B. B., Patel, D., & O'Hara, K. A. (2008). Mechanisms of myocyte cytotoxicity induced by the multiple receptor tyro-sine kinase inhibitor sunitinib. Molecular Pharmacology, 74, 1722-1728.
27. Pandit, B., Sarkozy, A., Pennacchio, L. A., Carta, C., Oishi, K., Martinelli, S., et al. (2007). Gain-of-function RAF1 mutations cause Noonan and LEOPARD syndromes with hypertrophic cardiomyopathy. Nature Genetics, 39, 1007-1012.
28. Hasinoff, N. B., & Patel, D. (2010). Mechanisms of myocyte cytotoxicity induced by the multikinase inhibitor sorafenib. Cardiovascular Toxicology, 10, 1-8.
29. Motzer, R. J., & Molina, A. M. (2009). Targeting renal cell carcinoma. Journal of Clinical Oncology, 27, 3312-3318.
30. Halimi, J. M., Azizi, M., Bobrie, G., Bouché, O., Deray, G., des Guetz, G., et al. (2008). Effets vasculaires et rénaux des médicaments anti-angiogéniques: Recommandations françaises pour la pratique (SN, SFHTA, APNET, FFCD). Néphrologie and Thérapeutique, 4, 602-615.
31. Ranpura, V., Pulipati, B., Chu, D., Zhu, X., & Wu, S. (2010). Increased risk of high-grade hypertension with bevacizumab in cancer patients: A meta-analysis. American Journal of Hypertension, 23, 460-468.
32. Scartozzi, M., Galizia, E., Chiorrini, S., Giampieri, R., Berardi, R., Pierantoni, C., et al. (2009). Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab. Annals of Oncology, 20, 227-230.
33. D'Adamo, D. R., Anderson, S. E., Albritton, K., Yamada, J., Riedel, E., Scheu, K., et al. (2005). Phase II study of doxoru-bicin and bevacizumab for patients with metastatic soft-tissue sarcomas. Journal of Clinical Oncology, 23, 7135-7142.
34. Ferroni, P., Formica, V., Roselli, M., & Guadagni, F. (2010). Thromboembolic events in patients treated with anti-angiogenic drugs. Current Vascular Pharmacology, 8, 102-113.
35. Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., et al. (2004). Bevacizumab plus iri-notecan, fluorouracil and leucovorin for metastatic colorectal cancer. New England Journal of Medicine, 350, 2335-2342.
36. Kabbinavar, F. F., Schulz, J., McCleod, M., Patel, T., Hamm, J. T., Hecht, J. R., et al. (2005). Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: Results of a randomized phase II trial. Journal of Clinical Oncology, 23, 3697-3705.
37. Nalluri, S. R., Chu, D., Keresztes, R., Zhu, X., & Wu, S. (2008). Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: A meta-analysis. JAMA, 300, 2277-2285.
38. Gieseler, F. (2008). Pathophysiological considerations to thrombophilia in the treatment of multiple myeloma with thalidomide and derivates. Thrombosis and Haemostasis, 99, 1001-1007.
39. Menon, S. P., Rajkumar, S. V., Lacy, M., Falco, P., & Palumbo, A. (2008). Thromboembolic events with lenalido-mide-based therapy for multiple myeloma. Cancer, 112, 1522-1528.
40. Sandler, A. B., Schiller, J. H., Gray, R., Dimery, I., Brahmer, J., Samant, M., et al. (2009). Johnson D.H.Retrospective evaluation of the clinical and radiographic risk factors associated with severe pulmonary hemorrhage in first-line advanced, unresec-table non-small-cell lung cancer treated with carboplatin and paclitaxel plus bevacizumab. Journal of Clinical Oncology, 27, 1405-1412.
41. Boehm, S., Rothermundt, C., Hess, D., & Joerger, M. (2010). Antiangiogenic drugs in oncology: A focus on drug safety and the elderly-A mini-review. Gerontology, 56, 303-309.
42. Barbey, J. T., Pezzullo, J. C., & Soignet, S. L. (2003). Effect of arsenic trioxide on QT interval in patients with advanced malignancies. Journal of Clinical Oncology, 21(19), 3609-3615.
43. Strevel, E. L., Ing, D. J., & Siu, L. L. (2007). Molecularly targeted oncology therapeutics and prolongation of the QT interval. Journal of Clinical Oncology, 25, 3362-3371.
44. Curigliano, G., Spitaleri, G., Fingert, H. J., de Braud, F., Sessa, C., Loh, E., et al. (2008). Drug-induced QTc interval prolongation: A proposal towards an efficient and safe anticancer drug development. European Journal of Cancer, 44, 494-500.
45. van Heeckeren, W. J., Bhakta, S., Ortiz, J., Duerk, J., Cooney, M. M., Dowlati, A., et al. (2006). Promise of new vascular-disrupting agents balanced with cardiac toxicity: Is it time for oncologists to get to know their cardiologists? Journal of Clinical Oncology, 24, 1485-1488.
46. Pai, V. B., & Nahata, M. C. (2000). Cardiotoxicity of chemo-therapeutic agents. Incidence, treatment and prevention. Drug Safety, 22, 263-302.
47. Belham, M., Kruger, A., Mepham, S., Faganello, G., & Prit-chard, C. (2007). Monitoring left ventricular function in adults receiving anthracycline-containing chemotherapy. European Journal of Heart Failure, 9, 409-414.
48. Jurcut, R., Wildiers, H., Ganame, J., D'hooge, J., Paridaens, R., & Voigt, J. U. (2008). Detection and monitoring of cardiotox-icity-what does modern cardiology offer? Supportive Care in Cancer, 16, 437-445.
49. Rowinsky, E. K., McGuire, W. P., Guarnieri, T., Fisherman, J. S., Christian, M. C., & Donehower, R. C. (1991). Cardiac disturbances during the administration of Taxol. Journal of Clinical Oncology, 9, 1704-1712.
50. Wortman, J. E., Lucas, V. S., Schuster, E., Thiele, D., & Logue, G. L. (1979). Sudden death during doxorubicin administration. Cancer, 44, 1588-1591.
51. Menard, O., Martinet, Y., & Lamy, P. (1991). Cisplatin-induced atrial fibrillation. Journal of Clinical Oncology, 9, 192-193.
52. Rezkalla, S., Kloner, R. A., Ensley, J., al-Sarraf, M., Revels, S., Olivenstein, A., et al. (1989). Continuous ambulatory ECG monitoring during fluorouracil therapy: A prospective study. Journal of Clinical Oncology, 7, 509-514.
53. van der Hooft, C. S., Heeringa, J., van Herpen, G., Kors, J. A., Kingma, J. H., & Stricker, B. H. (2004). Drug-induced atrial fibrillation. Journal of the American College of Cardiology, 44, 2117-2124.
54. Horacek, J. M., Jakl, M., Horackova, J., Pudil, R., Jebavy, L., & Maly, J. (2009). Assessment of anthracycline-induced cardio-toxicity with electrocardiography. Experimental Oncology, 31, 115-117.
55. Torti, F. M., Bristow, M. M., Lum, B. L., Carter, S. K., Howes, A. E., Aston, D. A., et al. (1986). Cardiotoxicity of epirubicin and doxorubicin: Assessment by endomyocardial biopsy. Cancer Research, 46, 3722-3727.
56. Piver, M. S., Marchetti, D. L., Parthasarathy, K. L., Bakshi, S., & Reese, P. (1985). Doxorubicin hydrochloride (Adriamycin) cardiotoxicity evaluated by sequential radionuclide angiocardiography. Cancer, 56, 76-80.
57. Schwartz, R., & Zaret, B. (1992). Diagnosis and treatment of drug induced myocardial disease. In F. C. Muggia & J. L. Spe-yer (Eds.), Cardiotoxicity of anticancer therapy (1st ed., pp. 173-197). Baltimore: Johns Hopkins University Press.
58. Palmeri, S. T., Bonow, R. O., Myers, C. E., Seipp, C., Jenkins, J., Green, M. V., et al. (1986). Prospective evaluation of doxo-rubicin cardiotoxicity by rest and exercise radionuclide angi-ography. American Journal of Cardiology, 58, 607-613.
59. Nousiainen, T., Vanninen, E., Jantunen, E., Remes, J., Kuikka, J., & Hartikainen, J. (2001). Anthracycline-induced cardiomy-opathy: Long-term effects on myocardial cell integrity, cardiac adrenergic innervation and fatty acid uptake. Clinical Physiology, 21, 123-128.
60. Valdés Olmos, R. A., ten Bokkel Huinink, W. W., ten Hoeve, R. F., van Tinteren, H., Bruning, P. F., van Vlies, B., et al. (1995). Assessment of anthracyclines-related myocardial adrenergic derangement by [123I] Metaiodobenzylguanidine scintigraphy. European Journal of Cancer, 31, 23-31.
61. Folland, E. D., & Parisi, A. F. (1979). Noninvasive evaluation of left ventricular function: The ejection fraction. Comprehensive Therapy, 5, 47-54.
62. Messina, L., Palmeri, S., Bonǹi, G., D'Alessandro, N., Rausa, L., & Raineri, A. (1981). Serial echocardiographic evaluation of subjects treated with adriamycin. Bollettino della Società itali-ana di cardiologia, 26, 2231-2237.
63. Hutter, J. J., Sahn, D. J., Woolfenden, J. M., & Carnahan, Y. (1981). Evaluation of the cardiac effects of doxorubicin by serial echocardiography. American Journal of Diseases of Children, 135, 653-657.
64. Jassal, D. S., Han, S. Y., Hans, C., Sharma, A., Fang, T., Ah-madie, R., et al. (2009). Utility of tissue Doppler and strain rate imaging in the early detection of trastuzumab and anthracycline mediated cardiomyopathy. Journal of the American Society of Echocardiography, 22, 418-424.
65. Nagy, A. C., Cserép, Z., Tolnay, E., Nagykálnai, T., & Forster, T. (2008). Early diagnosis of chemotherapy-induced cardiomy-opathy: A prospective tissue Doppler imaging study. Pathology oncology research, 14, 69-77.
66. Tei, C. (1995). New non-invasive index for combined systolic and diastolic ventricular function. Journal of Cardiology, 26, 135-136.
67. Hill, J. C., & Palma, R. A. (2005). Doppler tissue imaging for the assessment of left ventricular diastolic function: A systematic approach for the sonographer. Journal of the American Society of Echocardiography, 18, 80-90.
68. Quinones, M. A., Otto, C. M., & Stoddard, M. F. (2002). Recommendations for quantification of Doppler echocardiography: A report from the Doppler quantification task force of the nomenclature and standards committee of the American society of echocardiography. Journal of the American Society of Echocardiography, 15, 167-184.
69. Yuasa, T., Otsuji, Y., Kuwahara, E., Takasaki, K., Yoshifuku, S., Yuge, K., et al. (2005). Non-invasive prediction of complications with anteroseptal acute myocardial infarction by left ventricular Tei index. Journal of the American Society of Echocardiography, 18, 20-25.
70. Dodos, F., Halbsguth, T., Erdmann, E., & Hoppe, U. C. (2008). Usefulness of myocardial performance index and biochemical markers for early detection of anthracycline-induced cardio-toxicity in adults. Clinical Research Cardiology, 97, 318-326.
71. Senju, N., Ikeda, S., Koga, S., Miyahara, Y., Tsukasaki, K., Tomonaga, M., et al. (2007). The echocardiographic Tei-index reflects early myocardial damage induced by anthracyclines in patients with hematological malignancies. Heart and Vessels, 22, 393-397.
72. Rohde, L. E., Baldi, A., Weber, C., Geib, G., Mazzotti, N. G., Fiorentini, M., et al. (2007). Tei index in adult patients submitted to adriamycin chemotherapy: Failure to predict early systolic dysfunction. Diagnosis of adriamycin cardiotoxicity. International Journal of Cardiovascular Imaging, 23, 185-191.
73. Jurcut, R., Wildiers, H., Ganame, J., D'hooge, J., De Backer, J., Denys, H., et al. (2008). Strain rate imaging detects early cardiac effects of pegylated liposomal Doxorubicin as adjuvant therapy in elderly patients with breast cancer. Journal of the American Society of Echocardiography, 21, 1283-1289.
74. Piegari, E., Di Salvo, G., Castaldi, B., Vitelli, M. R., Rodolico, G., Golino, P., et al. (2008). Myocardial strain analysis in a doxorubicin-induced cardiomyopathy model. Ultrasound Medicine and Biology, 34, 370-378.
75. Hare, J. L., Brown, J. K., Leano, R., Jenkins, C., Woodward, N., Marwick, & T., H. Use of myocardial deformation imaging to detect preclinical myocardial dysfunction before conventional measures in patients undergoing breast cancer treatment with trastuzumab. American Heart Journal, 2009, 158:294-301.
76. Galderisi, M., Marra, F., Esposito, R., Lomoriello, V.S., Pardo, M., & de Divitiis, O. Cancer therapy and cardiotoxicity: The need of serial Doppler echocardiography. Cardiovascular Ultrasound, 2007, 5:4.
77. Jarfelt, M., Kujacic, V., Holmgren, D., Bjarnason, R., & Lannering, B. (2007). Exercise echocardiography reveals sub-clinical cardiac dysfunction in young adult survivors of childhood acute lymphoblastic leukemia. Pediatric Blood and Cancer, 49, 835-840.
78. Senior, R., & Lahiri, A. (2001). Role of dobutamine echocar-diography in detection of myocardial viability for predicting outcome after revascularization in ischemic cardiomyopathy. Journal of the American Society of Echocardiography, 14, 240-248.
79. Civelli, M., Cardinale, D., Martinoni, A., Lamantia, G., Colombo, N., Colombo, A., et al. (2006). Early reduction in left ventricular contractile reserve detected by dobutamine stress echo predicts high-dose chemotherapy-induced cardiac toxicity. International Journal of Cardiology, 111, 120-126.
80. Klewer, S. E., Goldberg, S. J., Donnerstein, R. L., Berg, R. A., & Hutter, J. J., Jr. (1992). Dobutamine stress echocardiography: A sensitive indicator of diminished myocardial function in asymptomatic doxorubicin-treated long-term survivors of childhood cancer. Journal of the American College of Cardiology, 19, 394-401.
81. Lanzarini, L., Bossi, G., Laudisa, M. L., Klersy, C., & Arico, M. (2000). Lack of clinically significant cardiac dysfunction during intermediate dobutamine doses in long-term childhood cancer survivors exposed to anthracyclines. American Heart Journal, 140, 315-323.
82. Bountioukos, M., Doorduijn, J. K., Roelandt, J. R., Vourvouri, E. C., Bax, J. J., Schinkel, A. F., et al. (2003). Repetitive dobutamine stress echocardiography for the prediction of anthracycline cardiotoxicity. European Journal of Echocardi-ography, 4, 300-305.
83. Hamada, H., Ohkubo, T., Maeda, M., & Ogawa, S. (2006). Evaluation of cardiac reserved function by high-dose dobuta-mine-stress echocardiography in asymptomatic anthracycline-treated survivors of childhood cancer. Pediatrics International, 48, 313-320.
84. Wu, K. C., Zerhouni, E. A., Judd, R. M., Lugo-Olivieri, C. H., Barouch, L. A., Schulman, S. P., et al. (1998). Prognostic significance of microvascular obstruction by magnetic resonance imaging in patients with acute myocardial infarction. Circulation, 97, 765-772.
85. Friedrich, M. G., Strohm, O., Schulz-Menger, J., Marciniak, H., Luft, F. C., & Dietz, R. (1998). Contrast media-enhanced magnetic resonance imaging visualizes myocardial changes in the course of viral myocarditis. Circulation, 97, 1802-1809.
86. Wassmuth, R., Hauser, I. A., Schuler, K., Schulz-Menger, J., Doerken, B., Dietz, R., et al. (2001). Subclinical cardiotoxic effects of anthracyclines as assessed by magnetic resonance imaging-A pilot study. American Heart Journal, 141, 1007-1013.
87. Hoffmann, R., von Bardeleben, S., Kasprzak, J. D., Borges, A. C., ten Cate, F., Firschke, C., et al. (2006). Analysis of regional left ventricular function by cineventriculography, cardiac magnetic resonance imaging and unenhanced and contrast enhanced echocardiography A multicenter comparison of methods. Journal of the American College of Cardiology, 47, 121-128.
88. Fallah-Rad, N., Lytwyn, M., Fang, T., Kirkpatrick, I., & Jassal, D.S. Delayed contrast enhancement cardiac magnetic resonance imaging in trastuzumab induced cardiomyopathy Journal of cardiovascular magnetic resonance,. 2008, 10:5.
89. Francis, G. S., Benedict, C., Johnstone, D. E., Kirlin, P. C., Nicklas, J., Liang, C. S., et al. (1990). Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. Circulation, 82, 1724-1729.
90. Schmitt, K., Tulzer, G., Merl, M., Aichhorn, G., Grillenberger, A., Wiesinger, G., et al. (1995). Early detection of doxorubicin and daunorubicin cardiotoxicity by echocardiography: Diastolic vs systolic parameters. European Journal of Pediatrics, 154, 201-204.
91. Neri, B., De Scalzi, M., De Leonardis, V., Gemelli, M. T., Ghezzi, P., & Pacini, P. (1991). Preliminary study on behaviour of atrial natriuretic factor in anthracycline-related cardiac tox-icity. International Journal of Clinical Pharmacy and Research, 11, 75-81.
92. Bauch, M., Ester, A., Kimura, B., Victoria, B. E., Kedar, A., & Phillips, M. I. (1992). Atrial natriuretic peptide as a marker for doxorubicin induced cardiotoxic effects. Cancer, 69, 1492-1497.
93. Sundby Hall, K., Wiklund, T., Erikstein, B., Holte, H., Kval-heim, G., Heen Sommer, H., et al. (2001). Effects of doseintensive chemotherapy and radiotherapy on serum n-terminal proatrial natriuretic peptide in high-risk breast cancer patients. Breast Cancer Research Treatment, 67, 235-244.
94. Hall, K. S., Wiklund, T., Erikstein, B., Holte, H., Kvalheim, G., Sommer, H. H., Andersen, A., Skovlund, E., Bergh J., & Hall, C. Effects of dose-intensive chemotherapy and radiotherapy on serum n-terminal proatrial natriuretic peptide in high-risk breast cancer patients. Breast Cancer Research Treatment, 2001, 67, 235-44.
95. Dolci, A., Dominici, R., Cardinale, D., Sandri, M. T., & Panteghini, M. (2008). Biochemical markers for prediction of chemotherapy-induced cardiotoxicity: Systematic review of the literature and recommendations for use. American Journal of Clinical Pathology, 130, 688-695.
96. Knobloch, K., Tepe, J., Lichtinghagen, R., Luck, H. J., & Vogt, P. M. (2008). Simultaneous hemodynamic and serological car-diotoxicity monitoring during immunotherapy with trastuzumab. International Journal of Cardiology, 125, 113-115.
97. Gaze, D. C., & Collinson, P. O. (2005). Cardiac troponins as biomarkers of drug-and toxin-induced cardiac toxicity and cardioprotection. Expert opinion on drug metabolism and toxicology, 1, 715-725.
98. Horacek, J. M., Pudil, R., Tichy, M., Jebavy, L., Strasova, A., Ulrychova, M., et al. (2008). Cardiac troponin I seems to be superior to cardiac troponin T in the early detection of cardiac injury associated with anthracycline treatment. Onkologie, 31, 511-512.
99. Cardinale, D., Colombo, A., Torrisi, R., Sandri, M. T., Civelli, M., Salvatici, M., et al. (2010). Trastuzumab-induced cardio-toxicity: Clinical and prognostic implications of troponin I evaluation. Journal of Clinical Oncology, 28, 3901-3904.
100. Yamashita, J., Ogawa, M., & Shirakusa, T. (1995). Plasma endothelin-1 as a marker for doxorubicin cardiotoxicity. International Journal of Cancer, 62, 542-547.
101. Zsáry, A., Szûcs, S., Keltai, K., Schneider, T., Rosta, A., Sármán, P., et al. (2004). Endothelins: A possible mechanism of cytostatics-induced cardiomyopathy. Leuk. Lymphom., 45, 351-355.
102. Bien, S., Riad, A., Ritter, C. A., Gratz, M., Olshausen, F., Westermann, D., Grube, M., Krieg, T., Ciecholewski, S., Felix, S. B., Staudt, A., Schultheiss, H. P., Ewert, R., Völker, U., Tschöpe, & C., Kroemer, H.K. The endothelin receptor blocker bosentan inhibits doxorubicin-induced cardiomyopathy. Cancer Research, 2007, 10428-35.
103. Miyagawa, K., Emoto, N., Widyantoro, B., Nakayama, K., Yagi, K., Rikitake, Y., et al. (2010). Attenuation of Doxorubicin-induced cardiomyopathy by endothelin-converting enzyme-1 ablation through prevention of mitochondrial biogenesis impairment. Hypertension, 55, 738-746.
104. Bristow, M. R., & Long, C. S. (2002). Cardiotrophin-1 in heart failure: Editorial. Circulation, 106, 1430-1432.
105. Calabrò, P., Limongelli, G., Riegler, L., Maddaloni, V., Calmieri, R., Golia, E., et al. (2009). Novel insights into the role of cardiotrophin-1 in cardiovascular diseases. Journal of Molecular and Cellular Cardiology, 46, 142-148.
106. Arimoto, T., Takeishi, Y., Shiga, R., Fukui, A., Tachibana, H., Nozaki, N., et al. (2005). Prognostic value of elevated circulating heart-type fatty acid binding protein in patients with congestive heart failure. Journal of Cardiac Failure, 11, 56-60.
107. Li, Y. M., Guo, Y. P., & Liu, Y. (2010). Cancer chemotherapy induces cardiotoxicity by targeting cardiac stem cells. Journal of cellular and molecular medicine, 14(11), 2630-2632.
108. De Angelis, A., Piegari, E., Cappetta, D., Marino, L., Filippelli, A., Berrino, L., et al. (2010). Anthracycline cardiomyopathy is mediated by depletion of the cardiac stem cell pool and is rescued by restoration of progenitor cell function. Circulation, 121(2), 276-292.
109. Kocher, A. A., Schuster, M. D., Szabolcs, M. J., Takuma, S., Burkhoff, D., Wang, J., et al. (2001). Neovascularization of ischemic myocardium by human bone-marrow-derived angio-blasts prevents cardiomyocyte apoptosis, reduces remodeling and improves cardiac function. Nature Medicine, 7, 430-436.
110. Nishikawa, S., Goldstein, R. A., & Nierras, C. R. (2008). The promise of human induced pluripotent stem cells for research and therapy. Nature Reviews. Molecular Cell Biology, 9, 725-729.
111. Nelson, T. J., Martinez-Fernandez, A., Yamada, S., Perez-Terzic, C., Ikeda, Y., & Terzic, A. (2009). Repair of acute myocardial infarction with iPS induced by human stemness factors. Circulation, 120(5), 408-416.
112. Colombo, S., Soranzo, N., Rotger, M., Sprenger, R., & Bleiber, G. (2005). Furrer H.l. Influence of ABCB1, ABCC1, ABCC2, and ABCG2 haplotypes on the cellular exposure of nelfinavir in vivo. Pharmacogenet Genomics, 15, 599-608.
113. + channels promote pause-induced spontaneous diastolic activity in long QT syndrome type 3 myocytes. Circulation Research, 99, 1225-1232.
114. Noord, C., EiJgeselsheim, M., & Stricker, B. H. (2010). Drug-and non-drug-associated QT interval prolongation. British Journal of Clinical Pharmacology, 70, 16-23.
115. Ewer, M. S., & Ewer, S. M. (2010). Cardiotoxicity of anticancer treatments: What the cardiologist needs to know. Nature Reviews Cardiology, 7(10), 564-575.